These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19007046)

  • 21. Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits.
    Petraitiene R; Petraitis V; Hope WW; Walsh TJ
    Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S643-51. PubMed ID: 26567283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin.
    Neofytos D; Huang YT; Cheng K; Cohen N; Perales MA; Barker J; Giralt S; Jakubowski A; Papanicolaou G
    Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S652-61. PubMed ID: 26567284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different doses of micafungin for prophylaxis of invasive fungal diseases in hemato-oncological high-risk patients: a web-based non-interventional trial in four large university hospitals in Germany.
    Heimann SM; Vehreschild MJ; Meintker L; Heinz W; Schroeder T; von Bergwelt-Baildon M; Cornely OA; Vehreschild JJ
    Transpl Infect Dis; 2014 Dec; 16(6):968-74. PubMed ID: 25371351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies.
    Toubai T; Tanaka J; Ota S; Shigematsu A; Shono Y; Ibata M; Hashino S; Kondo T; Kakinoki Y; Masauzi N; Kasai M; Iwasaki H; Kurosawa M; Asaka M; Imamura M
    Intern Med; 2007; 46(1):3-9. PubMed ID: 17202726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Micafungin Plasma Levels Are Not Affected by Continuous Renal Replacement Therapy: Experience in Critically Ill Patients.
    Vossen MG; Knafl D; Haidinger M; Lemmerer R; Unger M; Pferschy S; Lamm W; Maier-Salamon A; Jäger W; Thalhammer F
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
    Boonstra JM; van der Elst KC; Veringa A; Jongedijk EM; Brüggemann RJ; Koster RA; Kampinga GA; Kosterink JG; van der Werf TS; Zijlstra JG; Touw DJ; Alffenaar JWC
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Micafungin: a brief review of pharmacology, safety, and antifungal efficacy in pediatric patients.
    Lehrnbecher T; Groll AH
    Pediatr Blood Cancer; 2010 Aug; 55(2):229-32. PubMed ID: 20583216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic and safety profiles of repeated-dose prophylactic micafungin in children and adolescents undergoing hematopoietic stem cell transplantation.
    Albano E; Azie N; Roy M; Townsend R; Arrieta A
    J Pediatr Hematol Oncol; 2015 Jan; 37(1):e45-50. PubMed ID: 25072363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effective blood concentration of micafungin for pulmonary aspergillosis.
    Shimoeda S; Ohta S; Kobayashi H; Yamato S; Sasaki M; Kawano K
    Biol Pharm Bull; 2006 Sep; 29(9):1886-91. PubMed ID: 16946503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection.
    García-de-Lorenzo A; Luque S; Grau S; Agrifoglio A; Cachafeiro L; Herrero E; Asensio MJ; Sánchez SM; Roberts JA
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5914-21. PubMed ID: 27458229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intracellular concentrations of micafungin in different cellular compartments of the peripheral blood.
    Farowski F; Cornely OA; Vehreschild JJ; Bauer T; Hartmann P; Steinbach A; Vehreschild MJ; Scheid C; Müller C
    Int J Antimicrob Agents; 2012 Mar; 39(3):228-31. PubMed ID: 22230332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-Dose Micafungin for Preterm Neonates and Infants with Invasive and Central Nervous System Candidiasis.
    Auriti C; Falcone M; Ronchetti MP; Goffredo BM; Cairoli S; Crisafulli R; Piersigilli F; Corsetti T; Dotta A; Pai MP
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7333-7339. PubMed ID: 27697761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.
    Maseda E; Grau S; Luque S; Castillo-Mafla MP; Suárez-de-la-Rica A; Montero-Feijoo A; Salgado P; Gimenez MJ; García-Bernedo CA; Gilsanz F; Roberts JA
    Crit Care; 2018 Apr; 22(1):94. PubMed ID: 29655372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Micafungin twice weekly as antifungal prophylaxis in paediatric patients at high risk for invasive fungal disease.
    Bochennek K; Balan A; Müller-Scholden L; Becker M; Farowski F; Müller C; Groll AH; Lehrnbecher T
    J Antimicrob Chemother; 2015 May; 70(5):1527-30. PubMed ID: 25564562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Experience of micafungin in patients requiring extrarenal depuration].
    Alvarez-Lerma F; Grau S; Díaz Y; Fernández J
    Rev Esp Quimioter; 2010 Dec; 23(4):184-9. PubMed ID: 21191556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation.
    Autmizguine J; Hornik CP; Benjamin DK; Brouwer KL; Hupp SR; Cohen-Wolkowiez M; Watt KM
    Pediatr Infect Dis J; 2016 Nov; 35(11):1204-1210. PubMed ID: 27314826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of micafungin versus extensive azoles in the prevention and treatment of invasive fungal infections for neutropenia patients with hematological malignancies: A meta-analysis of randomized controlled trials.
    Lee CH; Lin JC; Ho CL; Sun M; Yen WT; Lin C
    PLoS One; 2017; 12(7):e0180050. PubMed ID: 28700646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of micafungin area under the curve data by using peak concentration: applicability and utility in antifungal therapy.
    Srinivas NR
    Future Microbiol; 2016; 11(4):485-90. PubMed ID: 27070500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.
    Groll AH; Mickiene D; Petraitis V; Petraitiene R; Ibrahim KH; Piscitelli SC; Bekersky I; Walsh TJ
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3322-7. PubMed ID: 11709303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of prophylactic micafungin in very-low-birth-weight infants.
    Kawada M; Fukuoka N; Kondo M; Okazaki K; Kusaka T; Kawada K; Itoh S
    Pediatr Infect Dis J; 2009 Sep; 28(9):840-2. PubMed ID: 19636279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.